Skip to main content
. 2019 Aug 14;19:809. doi: 10.1186/s12885-019-5971-z

Fig. 1.

Fig. 1

PFS of the different EOT MRD level groups, and according to IGHV mutational status. (A) PFS of the different MRD level groups at EOT in the whole population (both p < 0.0001 for low versus intermediate and low versus high levels). (B) PFS according to EOT MRD status (detectable versus undetectable) in IGHV-unmutated patients (p = 0.0206). (C) PFS according to EOT MRD status (detectable versus undetectable) in IGHV-mutated patients (p = 0.0002). EOT: end of treatment, MRD: minimal residual disease